4.8 Article

Network connectivity determines cortical thinning in early Parkinson's disease progression

期刊

NATURE COMMUNICATIONS
卷 9, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-017-02416-0

关键词

-

资金

  1. Michael J. Fox Foundation for Parkinson's Research
  2. AbbVie
  3. Avid
  4. Biogen
  5. Bristol-Myers Squibb
  6. Covance
  7. GE Healthcare
  8. Genentech
  9. GlaxoSmithKline
  10. Lilly
  11. Lundbeck
  12. Merck
  13. Meso Scale Discovery
  14. Pfizer
  15. Piramal
  16. Roche
  17. Sanofi Genzyme
  18. Servier
  19. Teva
  20. UCB
  21. W. Garfield Weston Foundation
  22. Alzheimer's Association
  23. Canadian Institutes of Health Research
  24. Natural Sciences and Engineering Research Council of Canada
  25. Canadian Institute of Health Research
  26. Jeanne Timmins Costello Fellowship

向作者/读者索取更多资源

Here we test the hypothesis that the neurodegenerative process in Parkinson's disease (PD) moves stereotypically along neural networks, possibly reflecting the spread of toxic alpha-synuclein molecules. PD patients (n = 105) and matched controls (n = 57) underwent T1-MRI at entry and 1 year later as part of the Parkinson's Progression Markers Initiative. Over this period, PD patients demonstrate significantly greater cortical thinning than controls in parts of the left occipital and bilateral frontal lobes and right somatomotor-sensory cortex. Cortical thinning is correlated to connectivity (measured functionally or structurally) to a disease reservoir evaluated by MRI at baseline. The atrophy pattern in the ventral frontal lobes resembles one described in certain cases of Alzheimer's disease. Our findings suggest that disease propagation to the cortex in PD follows neuronal connectivity and that disease spread to the cortex may herald the onset of cognitive impairment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据